Trial Profile
STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Heparin; Methotrexate; Prednisone; Vincristine
- Indications T-cell lymphoma
- Focus Therapeutic Use
- Acronyms Revail
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2019 This study has been completed in Belgium.
- 04 Dec 2018 Results of a final analysis of clinical and molecular data presented at the 60th Annual Meeting and Exposition of the American Society of Hematology